Last updated: 2026-10-14 10:41:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Opus Genetics, Inc. (IRD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.28, with a market capitalisation of $386.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.70 to $7.07. This page covers its latest market performance, valuation, price trends and company information.
$386.03M | |
$4.43 | |
$7.07 | |
$0.65 | |
$4.24 | |
3.67K | |
2.43M | |
-- | |
$7.07 | |
$1.70 | |
-- | |
-- |
Opus Genetics, Inc. (IRD) is trading at $4.28 in pre-market trading as of 2026-10-14 10:05:00, up 0.83% ($0.04) from the previous close of $4.24
Pre-market trading shows how investors are pricing IRD before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Opus Genetics, Inc. (IRD) moved from $4.38 to $4.28, representing a decline of 2.40% ($0.10).
The stock traded between $4.19 and $4.88 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.78 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 48.0%
IRD is currently trading at $4.28, placing it 48.0% of the way from its 52-week low of $1.70 to its 52-week high of $7.07. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Opus Genetics, Inc. (IRD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.